Amjevita(Cf) Autoinjector (Adalimumab-Atto) Patent Expiration, LOE Window & CMS Spending

Amjevita(Cf) Autoinjector (Adalimumab-Atto) by Amgen: Biologic BLA (Purple Book Regime), 0 AB generics, $71.8M 2024 CMS Part D & Medicaid spend, and $6,576 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmgen
FDA Application & PathwayB761024 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$71.8M
2024 Medicare Part D Spend$36.9M
2024 Medicaid Spend$34.9M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($6,576 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.